Results from an ongoing study that compares the efficacy of Genentech's Avastin and Lucentis in treating "wet" age-related macular degeneration may affect Medicare coverage of the eye drugs, raising financial stakes for the biotech firm. CMS officials said it would be cheaper to treat patients with Avastin, which costs $60 per treatment, compared with Lucentis, which costs $2,000 per dose. Genentech thinks Lucentis is the best treatment for the condition regardless of the study's outcome, a company spokeswoman said.

Full Story:

Related Summaries